DSP Healthcare Fund - Growth - Regular Plan

Other Plans and Options
  • 0.59 %Nav, as on 02-07-2020

  • Previous Nav

  • Net Change on 02-07-2020

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The primary investment objective of the scheme is to seek to generate consistent returns bypredominantly investing in equity and equity related securities of pharmaceutical and healthcarecompanies.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
S&P BSE Health Care 2.96 36.05 25.77 4.68 -0.38 13.91

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund-Growth Plan-Growth Jun 05, 2004 33.07 13.70 7.11 2.24 2,991.57
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH Jul 14, 1999 32.20 4.94 0.53 2.33 1,138.75
UTI Healthcare Fund - Regular Plan - Growth Option Aug 01, 2005 31.23 7.38 2.14 2.53 474.52

Fund Holdings as on 31-May-2020

  • Dr. Reddy's Laboratories Limited

  • JB Chemicals & Pharmaceuticals Limited

  • IPCA Laboratories Limited

  • Divi's Laboratories Limited

  • TREPS / Reverse Repo Investments / Corporate Debt Repo

  • Torrent Pharmaceuticals Limited

  • Indoco Remedies Limited

  • Sun Pharmaceutical Industries Limited

  • Alembic Pharmaceuticals Limited

  • Aarti Drugs Limited

  • Abbott Laboratories

  • Jubilant Life Sciences Limited

  • Procter & Gamble Health Limited

  • Narayana Hrudayalaya Ltd.

  • Abiomed Inc

  • Abbott India Limited

  • Syngene International Limited

  • Dr. Lal Path Labs Ltd.

  • ICICI Lombard General Insurance Company Limited

  • Intuitive Surgical Inc

  • Max India Limited

  • Ajanta Pharma Limited

  • Unichem Laboratories Limited

  • Cipla Limited

  • Apollo Hospitals Enterprise Limited

  • Alkem Laboratories Limited

  • Net Receivables/Payables

View More

  • Pharmaceuticals & Drugs

  • Miscellaneous

  • Hospital & Healthcare Services

  • Chemicals

  • Insurance

  • Finance - Investment

View More

Fund Manager

  • Education:B.Com, M Sc Finance, MBA
  • Experience:
  • Basic Details:Aditya has worked across the world, including in the US, EU, Latin America and in India. He started his career working with Glenmark Pharma in 2005 and worked in Brazil and Argentina. He then moved to Lehman Brothers(US) in 2007 and covered US generics companies like Teva, Mylan etc. He then worked with Nomura (UK) in 2008, covering MNC Pharma companies like GSK,Novartis, Sanofi among others, moving to Nomura India in 2011, where he started coverage of Indian Healthcare sector. Aditya joined DSP in 2015. He has an MSc.(Finance), PGDM (MDI,Gurgaon),CIIA (UK),CFA (ICFAI).
  • Funds Managed:
  • DSP Healthcare Fund
  • DSP Healthcare Fund

  • Cash

  • Equity

View More

About DSP Healthcare Fund

Scheme Analysis

DSP Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to DSP Mutual Fund. It was launched on 30-Nov-2018 and currently has an AUM of ₹412.35 crore. DSP Healthcare Fund is benchmarked against S&P BSE Health Care as primary index.

The NAV of DSP Healthcare Fund ended up ₹0.08(0.59%)yesterday to ₹13.687.

Among its top 3 holdings the fund has exposure to Dr. Reddy's Laboratories Limited, and

The DSP Healthcare Fund is managed by Vinit Sambre and Jay Kothari.

Fund House Contact

Mafatlal Centre, 10th Floor, Nariman Point, Mumbai - 400 021

+91 (22) 66578000
+91 (22) 66578181